I’m happy to report there have been a number of exciting developments reported at the EULAR (European League Against Rheumatism) meetings in Barcelona this spring, several of which may be of interest to you.
1). Prexige and Osteoarthritis. This medication is a new generation COX-2 selective nonsteroidal anti-inflammatory, manufactured by Novartis. In one clinical study of almost 800 hypertensive patients with osteoarthritis aged 50 and older, Prexige taken once a day showed a significant...
